Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

European Haematology Association

- PMLiVE

Bristol Myers Squibb announces positive trial results for treatment of MS

In the two phase 3 trials, Zeposia treatment showed improved or preserved cognitive function in the majority of patients

- PMLiVE

It’s a Medscape wrap for EHA2022

EHA2022 Hybrid Congress has now come to a close with the Thematic Days finishing last week. The Medscape team were delighted to connect with so many physicians, colleagues and supporters...

Medscape Education Global

Part 4 of 4, of the Medscape video interview series

Dr. Hansa Bhargava MD interviews Dr. Maria Victoria Mateos on the most important abstracts to look out for in multiple myeloma and the potential implications of these data for managing patients...

Medscape Education Global

- PMLiVE

AbbVie submits Parkinson’s disease therapy to FDA

The therapy offers a first-of-its-kind, 24-hour, continuous subcutaneous delivery

- PMLiVE

Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment

Plaque psoriasis is a chronic, systemic immune-mediated disease associated with multiple serious comorbidities

- PMLiVE

AbbVie’s Crohn’s disease drug given green light by MHRA

An estimated 217,000 people aged 16 and over live with the condition in the UK

- PMLiVE

AbbVie ends partnership with BioArctic to develop treatment for Parkinson’s disease

Results supporting phase 2 trials were presented at the International Congress of Parkinson’s Disease and Movement Disorders in September 2021

- PMLiVE

BMS Foundation announces Robert A Winn Diversity in Clinical Trials Award Program

The $100m initiative was started in 2020 to increase diversity in clinical trials

- PMLiVE

AbbVie’s Rinvoq accepted by SMC for atopic dermatitis

Scotland is the first nation in the UK to approve NHS access for the drug

- PMLiVE

FDA approves BMS’s Opdualag for metastatic or unresectable melanoma

The new, first-in-class fixed-dose dual immunotherapy combination treatment is administered as a single intravenous infusion

- PMLiVE

Sanofi reveals $330m collaboration with Blackstone Life Sciences

The partnership will focus on innovative treatment for multiple myeloma

- PMLiVE

AbbVie shares positive phase 3 results for migraine drug Qulipta

The impact of chronic migraines on patients can be debilitating

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links